Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings reported a record revenue of $4.1 million for Q4 2021, up from $2.3 million in Q4 2020. The company achieved a gross margin of approximately 59%. They booked 30 EksoNR units and posted a reduced net loss of $2.9 million, down from $4.0 million YoY. For the full year, revenue was $11.2 million, marking a 27% increase from 2020. Cash on hand rose to $40.4 million. Management appointed Steven Sherman as CEO and Scott Davis as President/COO, emphasizing their focus on innovation in neurorehabilitation.

Ekso Bionics Holdings (Nasdaq: EKSO) will release its financial results for Q4 and full year 2021 on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. The live webcast will be accessible on the company's website. Founded in 2005, Ekso Bionics specializes in exoskeleton technology aimed at enhancing mobility and strength in medical and industrial sectors.

Ekso Bionics Holdings announced the departure of CEO Jack Peurach effective January 21, 2022, to pursue other endeavors. Steven Sherman, the current Chairman, will step in as CEO starting January 22, 2022, while Scott Davis is promoted to President and COO. The board expressed confidence in future growth after reporting record revenue for Q4, driven by momentum in rehabilitation and industrial segments. Sherman aims to expand the product portfolio and align his compensation with shareholder interests by opting for equity over cash salary.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported record preliminary revenue for Q4 2021 between $3.9 million and $4.1 million, showing a 77% increase from Q4 2020's $2.3 million. Total revenue for fiscal 2021 reached an estimated $11.1 million to $11.3 million, up 26% from $8.9 million in 2020. Cash on hand surged to $40.4 million from $12.9 million a year earlier. CEO Jack Peurach indicated strong growth in both rehabilitation and industrial sectors, enhancing their market presence.

Ekso Bionics, a leader in exoskeleton technology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The management will engage in a fireside chat available on-demand starting January 10 at 4:00 AM PT. This chat will be accessible throughout the conference on the company's investor website. Founded in 2005, Ekso Bionics aims to enhance strength and mobility through innovative wearable robots. The company is publicly traded on Nasdaq under the symbol EKSO.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has appointed Corinna E. Lathan, Ph.D., to its Board of Directors. Dr. Lathan brings over 20 years of experience in robotics and biomedical engineering, having co-founded AnthroTronix. She currently serves on the board of PTC, Inc. and has held academic positions at prominent universities. CEO Jack Peurach expressed confidence in Dr. Lathan's ability to provide unique insights as the company aims to advance its innovative exoskeleton technologies for medical and industrial applications.

Ekso Bionics Holdings announced a significant partnership with the Fraternal Order of Eagles to enhance patient care in Nebraska. The EksoNR devices will be donated to Bryan Medical Center and Nebraska Methodist Hospital, benefiting over 60% of patients. This innovative technology aims to improve rehabilitation outcomes for patients with spinal cord injuries, strokes, and brain injuries. The initiative underscores Ekso's commitment to advanced rehabilitation and support for healthcare providers.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported a revenue of $3.0 million for Q3 2021, a slight increase from $2.9 million in Q3 2020. The gross margin was approximately 59%, down from 63% the previous year. The company booked 16 EksoNR units and maintained a strong cash position of $43.4 million. Despite increased revenues from EksoHealth, the net loss applicable to common stockholders for the quarter was $2.0 million, contrasting with a net income of $2.5 million during the same period in 2020.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q3 2021 on November 2, after market close. Management will discuss these results in a conference call at 1:30 p.m. PT/4:30 p.m. ET. A live webcast will be accessible in the 'Investors' section on the company's website. For those unable to attend, a replay will be available for two weeks. Ekso Bionics specializes in exoskeleton solutions for medical and industrial applications, enhancing strength and mobility for users.